Skip to main content
Donate

February 2025: Advocacy updates and actions to take

The Foundation for Angelman Syndrome Therapeutics (FAST) and the Angelman Syndrome Foundation (ASF) continue to work collaboratively on matters related to advocacy.

While we are disappointed that our EL-PFDD meeting has been postponed, we look forward to new ways to take action.

Please review the most recent updates and tools, taking action on anything that resonates with you and your family: 

  • Join us for the 2025 AS Congressional Advocacy Day in Washington, DC and be sure to book your hotel by Feb 11th!  

  • Explore our new Advocacy toolkit to see how you can make a difference at the local level.  

  • Read the letter signed by ASF, FAST, and over 200 rare disease organizations to Trump Administration regarding rare disease policy priorities.

  • Let lawmakers know how Medicaid impacts your loved one and why it must be protected.  

Be sure to check them out on the Hope in Action Advocacy Website for all information related to joint advocacy work between our organizations!

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.